NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system

S Chen, Y Gu, H Yu, X Chen, T Cao, L Hu… - European journal of …, 2021 - Springer
Purpose In this paper, we aimed to evaluate the positron emission tomography (PET)
performance of, to the best of our knowledge, the third commercially available whole-body …

Unpaired whole-body MR to CT synthesis with correlation coefficient constrained adversarial learning

Y Ge, Z Xue, T Cao, S Liao - Medical Imaging 2019: Image …, 2019 - spiedigitallibrary.org
MR to CT image synthesis plays an important role in medical image analysis, and its
applications included, but not limited to PET-MR attenuation correction and MR only radiation …

The state of instrumentation for combined positron emission tomography and magnetic resonance imaging

P Vaska, T Cao - Seminars in nuclear medicine, 2013 - Elsevier
Efforts at developing instrumentation for combined positron emission tomography and magnetic
resonance imaging have gained considerable momentum in recent years, propelled in …

[HTML][HTML] Validation of MR-based attenuation correction of a newly released whole-body simultaneous PET/MR system

G Liu, T Cao, L Hu, J Zheng, L Pang, P Hu… - BioMed research …, 2019 - hindawi.com
The aim of this study was to validate quantitative performance of a newly released simultaneous
positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner, by …

Optical flow-based vascular respiratory motion compensation

K Yang, Z Zhang, M Li, T Cao… - IEEE Robotics and …, 2023 - ieeexplore.ieee.org
This letter develops a new vascular respiratory motion compensation algorithm, Motion-Related
Compensation (MRC), to conduct vascular respiratory motion compensation by …

[HTML][HTML] PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

…, Y Peng, X Yu, Y Gao, B Yuan, Q Zhu, T Cao… - Journal of Experimental …, 2018 - Springer
Background The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved
for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP …

UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated …

…, Y Liu, Y Liu, Y Peng, B Yuan, Y Fu, X Qi, Q Zhu, T Cao… - Cancer Letters, 2021 - Elsevier
The UHRF1 and CDC6, oncogenes play critical roles in therapeutic resistance. In the
present study, we found that UHRF1 mediates androgen receptor (AR)-regulated CDC6 …

[HTML][HTML] Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition

…, L Yin, Y Peng, Y Peng, Y Gao, B Yuan, Q Zhu, T Cao… - Oncogene, 2019 - nature.com
Ionizing radiation (IR) is a conventional cancer therapeutic, to which cancer cells develop
radioresistance with exposure. The residual cancer cells after radiation treatment also have …

[HTML][HTML] FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness

…, Y Liu, X Yu, L Yin, Y Peng, Y Gao, Q Zhu, T Cao… - Cell Death & …, 2018 - nature.com
Therapy-induced expansion of cancer stem cells (CSCs) has been identified as one of the
most critical factors contributing to therapeutic resistance, but the mechanisms of this …

[HTML][HTML] USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis

…, Y Liu, Y Gao, B Yuan, X Qi, Y Fu, Q Zhu, T Cao… - Journal of Experimental …, 2019 - Springer
Background The deubiquitinase USP7 has been identified as an oncogene with key roles in
tumorigenesis and therapeutic resistance for a series of cancer types. Recently small …